Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. Ferrante M, et al. Among authors: bossuyt p. Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4. Lancet. 2022. PMID: 35644155 Clinical Trial.
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G. Drobne D, et al. Among authors: bossuyt p. Clin Gastroenterol Hepatol. 2015 Mar;13(3):514-521.e4. doi: 10.1016/j.cgh.2014.07.027. Epub 2014 Jul 25. Clin Gastroenterol Hepatol. 2015. PMID: 25066841
The course of anaemia in children and adolescents with Crohn's disease included in a prospective registry.
Van Biervliet S, Smets F, Hofmann I, Degreef E, Hauser B, Bontems P, Vande Velde S, Arts W, Paquot I, Alliet P, Bossuyt P, Louis E, Baert F, Bauraind O, Rahier JF, Veereman G. Van Biervliet S, et al. Among authors: bossuyt p. Int J Colorectal Dis. 2015 Jan;30(1):51-6. doi: 10.1007/s00384-014-2042-4. Epub 2014 Oct 30. Int J Colorectal Dis. 2015. PMID: 25354967
Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease.
D'Haens G, Löwenberg M, Samaan MA, Franchimont D, Ponsioen C, van den Brink GR, Fockens P, Bossuyt P, Amininejad L, Rajamannar G, Lensink EM, Van Gossum AM. D'Haens G, et al. Among authors: bossuyt p. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1480-6.e3. doi: 10.1016/j.cgh.2015.01.031. Epub 2015 Mar 21. Clin Gastroenterol Hepatol. 2015. PMID: 25804331
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group. Regueiro M, et al. Gastroenterology. 2016 Jun;150(7):1568-1578. doi: 10.1053/j.gastro.2016.02.072. Epub 2016 Mar 3. Gastroenterology. 2016. PMID: 26946343 Free article. Clinical Trial.
Primetime for e-health in IBD?
Bossuyt P, Pouillon L, Peyrin-Biroulet L. Bossuyt P, et al. Nat Rev Gastroenterol Hepatol. 2017 Mar;14(3):133-134. doi: 10.1038/nrgastro.2017.11. Epub 2017 Jan 25. Nat Rev Gastroenterol Hepatol. 2017. PMID: 28119535 No abstract available.
Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases.
Ghosh S, Louis E, Beaugerie L, Bossuyt P, Bouguen G, Bourreille A, Ferrante M, Franchimont D, Frost K, Hebuterne X, Marshall JK, OʼShea C, Rosenfeld G, Williams C, Peyrin-Biroulet L. Ghosh S, et al. Among authors: bossuyt p. Inflamm Bowel Dis. 2017 Mar;23(3):333-340. doi: 10.1097/MIB.0000000000001033. Inflamm Bowel Dis. 2017. PMID: 28146002 Free PMC article.
Tofacitinib Is the Right OCTAVE for Ulcerative Colitis.
Pouillon L, Bossuyt P, Peyrin-Biroulet L. Pouillon L, et al. Among authors: bossuyt p. Gastroenterology. 2017 Sep;153(3):862-864. doi: 10.1053/j.gastro.2017.07.027. Epub 2017 Jul 27. Gastroenterology. 2017. PMID: 28757262 No abstract available.
1,126 results